A. Mori

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Hope S. Rugo, Richard S. Finn, Véronique Dièras et al. · Breast Cancer Research and Treatment · 2019 · 442 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Hope S. Rugo, Véronique Dièras, Karen A. Gelmon et al. · Annals of Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Nicholas C. Turner, Richard S. Finn, Miguel Martín et al. · Annals of Oncology · 2018 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

Véronique Dièras, Hope S. Rugo, Patrick Schnell et al. · JNCI Journal of the National Cancer Institute · 2018 · 99 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial

Véronique Dièras, Nadia Harbeck, Anil A. Joy et al. · The Oncologist · 2019 · 95 citations · Full text

Medicine, Oncology, Pharmacology +15